跳到主要內容

臺灣博碩士論文加值系統

(18.204.48.64) 您好!臺灣時間:2021/08/01 09:17
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:孫子麒
研究生(外文):Sun Tzu Chi
論文名稱:免疫抑制型細胞激素培養之樹突細胞對胎鼠骨髓移植之效用評估
論文名稱(外文):The potential application of immune suppressive cytokine conditioned-dendritic cells on fetal mice bone marrow transplantation
指導教授:周秀慧周秀慧引用關係
指導教授(外文):Chou Shiu Huey
學位類別:碩士
校院名稱:輔仁大學
系所名稱:生命科學系碩士班
學門:生命科學學門
學類:生物學類
論文種類:學術論文
論文出版年:2007
畢業學年度:95
語文別:中文
論文頁數:95
中文關鍵詞:子宮內骨髓移植樹突細胞
外文關鍵詞:in utero transplantationDendriric cellTGF-beta1IL-10
相關次數:
  • 被引用被引用:3
  • 點閱點閱:125
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
子宮內骨髓移植是指在懷孕中期,將健康之骨髓細胞植入胎兒受體的技術,用於治療先前骨髓移植可以治療的疾病。但現階段所遇到的問題為植入率過低(0.1%),植入的細胞不足以治療疾病及無法引發免疫耐受力。樹突細胞是一種抗原呈現細胞,具有活化T細胞及引發T細胞對外來細胞產生耐受性的雙重特性。排斥反應是由宿主TH1所主導的,TGF-1與IL-10為免疫抑制型的細胞激素,可以抑制T細胞的增生,對於樹突細胞具有抑制其輔助刺激因子的表現使樹突細胞成為一種不成熟的狀態,而不成熟的樹突細胞具有引發免疫耐受力的功用。本實驗利用MHC-mismatched小鼠模式,將C57BL/6小鼠樹突細胞或經過TGF-1或TGF-1+IL-10培養後的樹突細胞與捐贈者(C57BL/6 GFP+ H-2b)之造血幹細胞共同植入13~14天BALB/c胎鼠中,以評估對於胎鼠骨髓移植的效用。首先評估13~15天的胎鼠在TGF-與IL-10受器的表現與TGF-1分泌的能力,結果顯示13天的胎鼠即具有40% TGF- RII與3.2% IL-10 R的表現,該時期免疫細胞具有被活化的能力,而免疫細胞也具產生及釋放 TGF-1的能力。接著經由C57BL/6小鼠骨髓在GM-CSF培養下分化出一群CD40low、CD80 low、CD86 low、B7-H1 hi與B7-DC med的樹突細胞,該細胞呈現微弱的吞噬能力並具有被外來抗原活化的能力,將該細胞經過TGF-1培養後發現其細胞表面輔助刺激因子CD40、CD80、CD86、B7-DC及MHC II的表現顯著的下降,而經過TGF-1+IL-10培養後也會降低CD40、CD86及B7-DC的表現,進一步將此兩組處理的樹突細胞與異體T細胞做單向淋巴球混合實驗,顯示具有抑制異體T細胞增生的能力,進一步分析發現經過與TGF-1或TGF-1+IL-10培養後的樹突細胞作用後的T細胞表面上CD28分子會下降而PD-1分子的表現會上昇,同時也使CD4+CD25+調節性T細胞族群有少量的增加。分析其上清液中細胞激素的表現,發現TGF-1與TGF-1+IL-10培養的樹突細胞均會抑制T細胞IL-2、IL-4、IL-10、IFN-的分泌,但前者卻會提昇TNF-的分泌;而後者卻是提昇TGF-1的分泌。在活體胎鼠骨髓移植發現共同注射處理與未處理之樹突細胞與造血幹細胞均具有提昇胎鼠骨髓移植的植入率,但經抑制型細胞激素處理的樹突細胞並未提昇植入細胞的數目。綜合以上的結果,體外實驗顯示經過TGF-1或TGF-1+IL-10培養可降低樹突細胞表面CD40、CD80與CD86輔助刺激因子的表現,進而降低與之接觸後異體T細胞CD28的表現與提昇PD-1與B7-H1的作用,因而引發抑制異體T細胞的增生反應。該負向調節反應雖可增加活體胎鼠移植的植入率但卻無法顯著的提昇植入細胞的數目。
In utero hematopoietic stem cell transplantation (IUHSCT) was used as strategy to replace bone marrow transplantation without the need of toxic conditioning therapy. The major limitation of IUT to date is limited chimerism and lack tolerance to alloantigen. Dendritic cells (DCs) are considered very potent antigen-presenting cells for T cell activation, but strongly tolerogenic as precursor DC. The major problem on failure of transplantation is that implant is rejected by recipient. Rejection of implant is mediated by type I T helper cells of host. TGF-β1 and IL-10 are kind of suppression cytokines. Related researches have reported that both cytokines inhibited the Th1 cell activation and DC maturation. Herein, we firstly investigated the expression level of TGF-β1 and IL-10 in 13-14-day fetus. Then, we measured the effects of TGF-1 or TGF-1+IL-10 cultured donor derived DCs on allogenic T cell responses by in vitro mix lymphocyte reaction assay (MLR). Furthermore, by using a MHC-mismatched mouse model, we examine the effects of TGF-1 and TGF-1+IL-10 DCs on in utero mice bone marrow transplantation. Results indicated that 13~15 days of pregnancy fetus posses the normal expression of TGF- receptor (40%) and IL-10 receptor (3.2%) on the surface of immune cells and production of TGF-1 cytokine (120pg/ml). Furthermore, 13-15 days of fetus exhibited the proliferate capability in response to mitogen stimulation. In this study, GM-CSF-derived bone marrow CD11c positive cells with expression of CD40 low, CD80 low, CD86 low, B7-H1 hi, and B7-DC med were acquired and used as a source of dendritic cells . Those cells had shown a weak phagocytic activity and can be activated by LPS stimulation. After culturing with immune suppressive cytokine, TGF-1 cultured DCs showed less expression on co-stimulatory molecules CD40, CD80, CD86, B7-DC and MHC class II, while TGF-1+IL-10 cultured DC showed less CD40, CD86 and B7-DC expression. By using mix lymphocyte assay, TGF-1 and TGF-1+IL-10 treated DCs inhibited the allogenic T cell proliferation through decreased CD28 expression and increased PD-1 on T cells. In addition, small numbers of CD4+CD25+ Foxp3 T cells were induced in co-cultured TGF-1 and TGF-1+IL-10 treated DCs with allogenic T cells. Further analysis of T cell cytokine production in cultures of MLR had showed that both TGF-1 and TGF-1+IL-10 treated DCs decreased the production of IL-2, IL-4, IL-10, and IFN-however, the production of TNF- was increased in former and production of TGF-1 was increased in later, respectively. In animal experiment, co-injected immune suppressive cytokine treated-DCs with donor bone marrow cells had increased engraftment of donor cells, but did not increase the number of donor cells in fetus recipients. In conclusion, TGF-1 or TGF-1+IL-10 conditioned DCs have induced the negative regulation in response to allogenic T cells. Although this negative regulation increased the engraftment of donor cells in fetal recipients, but the percentage of donor cells in recipients was not improved in this application.
目錄-----------------------------------------------------------------------------------------------------I

表目錄------------------------------------------------------------------------------------------------VI

圖目錄-----------------------------------------------------------------------------------------------VII

中文摘要----------------------------------------------------------------------------------------------1

英文摘要----------------------------------------------------------------------------------------------3

第一章 研究背景
第一節 骨髓移植與子宮內骨髓移植
1.1.1 骨髓移植的定義、應用與重要性------------------------------------------------5
1.1.2 骨髓移植的瓶頸與解決策略------------------------------------------------------5
1.1.3 子宮內骨髓移植的定義、應用與重要性---------------------------------------7
1.1.4 子宮內隨移植的瓶頸與動物研究模式------------------------------------------8

第二節 免疫排斥、免疫耐受性與移植
1.2.1 移植的排斥反應---------------------------------------------------------------------9
1.2.2 免疫排斥反應的理論基礎-------------------------------------------------------10
1.2.3 免疫耐受性-------------------------------------------------------------------------11
1.2.4 免疫耐受性與骨髓移植----------------------------------------------------------12


第三節 樹突細胞
1.3.1 樹突細胞的特性與生物活性----------------------------------------------------13
1.3.2 樹突細胞在器官以及骨髓移植上的應用-------------------------------------15
1.3.3 樹突細胞與子宮內骨髓移植的應用-------------------------------------------16

第四節 轉型生長因子- (Transforming Growth Factor-beta)
1.4.1 TGF-的生化特性-----------------------------------------------------------------18
1.4.2 TGF-受器與訊息傳導-----------------------------------------------------------19
1.4.3 TGF-的免疫活性-----------------------------------------------------------------20
1.4.4 TGF-在移植上的應用-----------------------------------------------------------22

第五節 合併免疫抑制型細胞激素介白質-10 (Interleukin-10) 與轉型生長因子-β1 (Transforming Growth Factor-beta;TGF-β1)
1.5.1 IL-10簡介----------------------------------------------------------------------------22
1.5.2 IL-10 的免疫活性------------------------------------------------------------------23
1.5.3 IL-10與TGF-β1 的合併在移植上的應用-------------------------------------24

第二章 研究目的與重要性------------------------------------------------------------------26

第三章 實驗材料及方法
第一節 實驗設計
part A:胎鼠體內環境的確認 (TGF-1的分泌與TGF-1 receptor的表現) ------27
part B: IL-10與TGF-1共同培養樹突細胞的體內與體外實驗-------------------28

第二節 實驗材料與方法
一、實驗小鼠---------------------------------------------------------------------------------29
二、實驗藥品、培養基與各類試劑-------------------------------------------------------29
三、儀器設倍----------------------------------------------------------------------------------37


第四節實驗方法
(I) 胎鼠、新生鼠和成鼠體內TGF-1的分泌與TGF-1 receptor的表現
1、胎鼠、新生鼠和成鼠免疫器官初代細胞之製備---------------------------39
2、胎鼠、新生鼠與成鼠免疫細胞對抗原增值能力評估---------------------39
3、胎鼠與成鼠免疫細胞細胞激素分析------------------------------------------40
4、胎鼠與成鼠免疫細胞表面TGF-β與IL-10 receptor蛋白表現的偵 測------------------------------------------------------------------------------------40
5、胎鼠與成鼠免疫細胞 TGF-β與IL-10 receptor mRNA的偵測----------41

(II) TGF-1 培養骨髓樹突細胞定性及免疫活性分析
1、 骨髓樹突細胞的置備-----------------------------------------------------------42
2、 骨髓樹突細胞TGF-β1 與IL-10/TGF-β1最佳培養濃度的備置--------42
3、 骨髓樹突細胞免疫活性分析
3-1 骨髓樹突細胞表面抗原分析-----------------------------------------------43
3-2 骨髓樹突細胞釋放一氧化氮能力評估-----------------------------------43
3-3 骨髓樹突細胞細胞激素釋放之測定--------------------------------------44
3-4 單向異體淋巴球混合實驗 (One-Way MLR Assay)--------------------44
3-5 樹突細胞與T細胞表面分子的改變--------------------------------------45
3-6 異體T細胞經由骨髓樹突細胞刺激後所分泌細胞激素的改變-----46
3-7 異體T細胞經由骨髓樹突細胞刺激後Foxp3的改變-----------------46

(III) TGF-1培養後骨髓樹突細胞對於胎鼠骨髓移植植入效用的評估
1、骨髓lin-造血幹細胞純化------------------------------------------------------46
2、子宮內骨髓移植手術----------------------------------------------------------47

(IV) 骨髓移植植入率的評估
1、接受者體內捐贈細胞之追蹤
1-1 血液檢體之取得-------------------------------------------------------------48
1-2 細胞表面抗原(H-2Kb)之染色-----------------------------------------48
1-3 檢體DNA 萃取與聚合酵素連鎖反應-----------------------------------49

(V) 統計分析--------------------------------------------------------------------------------49

第四章 結果
第一節 小鼠不同發生時期免疫細胞活性與TGF-β1及IL-10受器表現的評估
1. 胎鼠、新生鼠與成鼠免疫細胞活化增殖之活性評估---------------------------50
2. 胎鼠免疫組織中TGF-β receptor 以及IL-10 receptor 表現的評估------------51
3. 胎鼠及成鼠免疫器官釋放TGF-β1細胞激素能力之評估----------------------51

第二節 骨髓樹突狀細胞的定性及其活性測定
1. 骨髓樹突細胞表面抗原之表現-------------------------------------------------------52
2. 樹突細胞的活性分析
骨髓樹突細胞釋放NO以及細胞吞噬能力評估-----------------------------52
骨髓樹突細胞釋放細胞激素之能力--------------------------------------------53

第三節 免疫抑制型細胞激素 (TGF-β1 與 IL-10) 培養後之骨髓樹突細胞免疫功能的分析
1. 免疫抑制型細胞激素培養後對骨髓樹突細胞表面抗原表現影響之分析---54
2. 免疫抑制型細胞激素培養之骨髓樹突細胞釋放NO能力的評估-------------54

第四節 免疫抑制型細胞激素 TGF-β1 或/和 TGF-β1+IL-10 培養後之骨髓樹突細胞對異體 T 細胞的影響評估
1. 免疫抑制型細胞激素培養前後之骨髓細胞對於異體骨髓接受者之抗原性------------------------------------------------------------------------------------------------54
2. 免疫抑制型細胞激素培養後之樹突細胞對於異體接受者 T 細胞表面分子表驗影響的評估---------------------------------------------------------------------------55
3. 免疫抑制型細胞激素培養後之樹突細胞誘導異體 T 細胞產生細胞激素的估------------------------------------------------------------------------------------------56

第五節 TGF-β1 與 TGF-β1+IL-10 培養後的樹突細胞對胎兒和新生鼠骨髓造血幹細胞移植的評估
1. 子宮內骨髓移植------------------------------------------------------------------------56

第五章 討論-----------------------------------------------------------------------------------------58

參考文獻---------------------------------------------------------------------------------------------64
1.呂勻. IL-10培養之樹突細胞對小鼠子宮內骨髓移植效用之評估. 輔仁大學生命科學所碩士論文 (2005).

2.王怡文. In vitro determined the capacity of fetal immune cells to reject allogenic donor cells. 行政院國家科學委員會補助大專生參與專題研究計畫 (2007).

3.Ahuja SS, Paliogianni F, Yamada H, Balow JE, Boumpas DT. Effect of transforming growth factor-beta on early and late activation events in human T cells. J. Immunol (1993). 150:3109–18

4.Anderson D, Billingham R, Lampkin G & Medawar P. The use of skin grafting to distinguish between monozygotic and dizygotic twins in cattle. Heredity 1951; 5: 379–397.

5.Anke Zobywalski, Miran Javorovic, Bernhard Frankenberger, Heike Pohla, Elisabeth Kremmer, Iris Bigalke and Dolores J Schendel. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70 Journal of Translational Medicine 2007, 5:18

6.Attisano, L., Carcamo, J., Ventura, F., Weis, F. M., Massague´, J., Wrana, J. L. (1993) Identification of human activin and TGF type I receptors that form heteromeric kinase complexes with type II receptors. Cell 75, 671–680.

7.Archer DR, Turner CW, Yeager AM, Fleming WH. Sustained multilineage engraftment of allogeneic hematopoietic stem cells in NOD/SCID mice after in utero transplantation. Blood 1997;90(8):3222-9.

8.Ashok B. Kulkarni, Tamizchelvi Thyagarajan and John J. Letterio. Function of Cytokines within the TGF-b Superfamily as Determined from Transgenic and Gene Knockout Studies in Mice. Current Molecular Medicine 2002;2(3):303-327

9.Attisano L, C´arcamo J, Ventura F, Weis FMB, Massagu´e J, et al. 1993. Cell 75: 671–80

10.Bambach BJ, Moser HW, Blakemore K, et al. Engraftment following in utero bone marrow transplantation for globoid cell leukodystrophy. Bone Marrow Transplant 1997;19(4):399-402.

11.Bernstein J, Boyle DW, Srour EF, Cooper R, Jacobs C, Freie B, Liechty E, Clapp DW. Variation in long-term engraftment of a large consecutive series of lambs transplanted in utero with human hematopoietic cells. Biol Blood Marrow Transplant 1997;3(5):247-54.

12.Bhattacharyya S, Cowan MJ. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation. Biol Blood Marrow Transplant. 2005 Sep;11(9):657-71.

13.Billingham RE, Brent L, Medawar PB. 'Actively acquired tolerance' of foreign cells. 1953. Transplantation 2003;76(10):1409-12.

14.Billingham RE, Brent L. A simple method for inducing tolerance of skin homografts in mice. Transplant Bull 1957;4(2):67-71.

15.Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol 2000;18:767-811.

16.Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673):245-52.

17.Brocker T, Riedinger M, Karjalainen K. Targeted expression of major histocompatibility complex (MHC) class II molecules demonstrates that dendritic cells can induce negative but not positive selection of thymocytes in vivo. J Exp Med 1997;185(3):541-50.

18.Bogdan C, Nathan C. Modulation of macrophage function by transforming growth factor beta, interleukin- 4, and interleukin-10. Ann. NY Acad. Sci (1993). 685:713–39

19.Buckley R. H., 27. Transplantation immunology: organ and bone marrow. J Allergy Clin Immunol 2003;111(2 Suppl):S733-44.

20.Chcifetz, S., Weathcrbee, J. A., Tsang, M. L. S., Anderson, J. K., Mole, J. E., et al. 1987. The transforming growth factor-ft system, a complex pattern of cross-reactive ligands and receptors. Cell 48:409-15

21.Cheng J, Xia SS, Xie S, Tang LG, Shi XF. Transforming growth factor beta1-modified donor cell transfusion induced allo-heart tolerance. Transplant Proc. 2005. (5):2360-4.

22.Chou SH, Kuo TK, Liu M, Lee OK. In Utero Transplantation of huhman bone marrow-derived multipotent mesenchymal stem cellsin mice. J Orthop Res. 2006 24(3): 301-12

23.Chou SH, Kojic LD, Messingham KN, Cunnic JE. Characterization of the effect of 2-deoxy-D-glucose(2-DG) on the immune system. Brain Behav Immun 1996;10(4):399-416.

24.Cobbold SP, Nolan KF, Graca L, Castejon R, Le Moine A, Frewin M, Humm S, Adams E, Thompson S, Zelenika D, Paterson A, Yates S, Fairchild PJ, Waldmann H. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunol Rev. 2003 Dec;196:109-24.

25.Colas G, Hollands P, Locatelli A, et al. The xenotransplantation of goat and human hematopoietic cells to sheep fetuses. Transplantation 1999;67(7):984-90.

26.Cowan, M.J., Bone marrow transplantation for the treatment of genetic diseases. Clin Biochem 1991;24(4):375-81.

27.Dai Z, Lakkis FG. The role of cytokines, CTLA-4 and costimulation in transplant tolerance and rejection. Curr Opin Immunol. 1999 Oct;11(5):504-8.

28.Davoust J, Banchereau J. Naked antigen-presenting molecules on dendritic cells. Nat Cell Biol 2000;2(3):E46-8.

29.Del Prete G, De Carli M, Almerigogna F, Giudizi MG, Biagiotti R, Romagnani S. Human IL-10 is produced by both type 1 helper (Th1) and type 2 helper (Th2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol. 1993 . 15;150(2):353-60.

30.Demetris AJ, Murase N, Ye Q, et al. Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol 1997;150(2):563-78.

31.den Haan JM, Sherman NE, Blokland E, et al. Identification of a graft versus host disease-associated human minor histocompatibility antigen. Science 1995;268(5216):1476-80.

32.Derynck, R., Jarrett, J. A., Chen, E. Y., Eaton, D. H., Bell, J. R., et al. 1985. Human transforming growth factor- complementary DNA sequence and exmession in normal and transformed EMBO J. 6: 3673-77 ceils. Nature 316: 701-5

33.Derynck, R., Rhee, L., Chen, E. Y., Van Tilburg, A. 1987. Intron-exon structure of human transforming growth factor-8 precursor gene. Nucleic Acid.7 Res. 15: 3188- 89

34.Derynck, R., Lindquist, P. B., Lee, A,, Wen, D., Tamm, J., et al. 1988. A new type of transforming growth factor-8, TGF-83. EMBO J. 7: 373743

35.De Smedt T, Pajak B, Muraille E, et al. Regulation of dendritic cell numbers and maturation by lipopolysaccharide in vivo. J Exp Med 1996;184(4):1413-24.

36.Donahue J, Gilpin E, Lee TH, Busch MP, Croft M, Carrier E. Microchimerism does not induce tolerance and sustains immunity after in utero transplantation. Transplantation 2001;71(3):359-68.

37.Doney KC, Weiden PL, Storb R, Thomas ED. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. Am J Hematol 1981;11(1):1-8.

38.Duncan BW, Harrison MR, Crombleholme TM, Clemons G, Tavassoli M, Zanjani ED. Effect of erythropoietic stress on donor hematopoietic cell expression in chimeric rhesus monkeys transplanted in utero. Exp Hematol 1992;20(3):350-3.

39.Duncan SR, Capetanakis NG, Lawson BR, et al. Thymic dendritic cells traffic to thymi of allogeneic recipients and prolong graft survival. J Clin Invest. 2002;109:755-764.

40.Ebisawa, T., Fukuchi, M., Murakami, G., Chiba, T., Tanaka, K., Imamura, T., Miyazono, K. (2001) Smurf1 interacts with transforming growth factor- type I receptor through Smad7 and induces receptor degradation. J. Biol. Chem. 276, 12477–12480.

41.Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993;151(5):2390-8.

42.Evans MI, Harrison MR, Flake AW, Johnson MP. Fetal therapy. Best Pract Res Clin Obstet Gynaecol 2002;16(5):671-83.

43.Fairchild PJ, Waldmann H. Dendritic cells and prospects for transplantation tolerance. Curr Opin Immunol 2000;12(5):528-35.

44.Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. Blood 1999;94(7):2179-91.

45.Flake AW, Harrison MR, Adzick NS, Zanjani ED. Transplantation of fetal hematopoietic stem cells in utero: the creation of hematopoietic chimeras. Science 1986;233(4765):776-8.

46.Flake AW, Roncarolo MG, Puck JM, et al. Treatment of X-linked severe combined immunodeficiency by in utero transplantation of paternal bone marrow. N Engl J Med 1996;335(24):1806-10.

47.Flake AW, Zanjani ED. In utero hematopoietic stem cell transplantation: ontogenic opportunities and biologic barriers. Blood 1999;94(7):2179-91.

48.Flamand V, Sornasse T, Thielemans K, et al. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo. Eur J Immunol 1994;24(3):605-10.

49.Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C-H., Miyazono, K. (1993) Cloning of a TGF type I receptor that forms a heteromeric complex with the TGF type II receptor. Cell 75, 681–692.

50.Freeman, G., A. Long, Y. Iwai, K. Bourque, T. Chernova, H. Nishimura, L. Fitz, N. Malenkovich, B. Carreno, M. Collins, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 2000. 192:1027.

51.Fu F, Li Y, Qian S, Lu L, Chambers F, Starzl TE, Fung JJ, Thomson AW. Costimulatory molecule-deficient dendritic cell progenitors (MHC class II+, CD80dim, CD86-) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 1996;62(5):659-65.

52.Gammie JS, Pham SM. Simultaneous donor bone marrow and cardiac transplantation: can tolerance be induced with the development of chimerism? Curr Opin Cardiol 1999;14(2):126-32.

53.Gerlier D, Thomasset N. Use of MTT colorimetric assay to measure cell activation. J Immunol Methods 1986;94(1-2):57-63

54.Geissmann F, Revy P, Regnault A, Lepelletier Y, Dy M, Brousse N, Amigorena S, Hermine O, Durandy A. TGF-beta 1 prevents the noncognate maturation of human dendritic Langerhans cells. J Immunol. 1999 Apr 15;162(8):4567-75.

55.Good, R.A., Verjee T. Historical and current perspectives on bone marrow transplantation for prevention and treatment of immunodeficiencies and autoimmunities. Biol Blood Marrow Transplant 2001;7(3):123-35.

56.Grouard G, Durand I, Filgueira L, Banchereau J, Liu YJ. Dendritic cells capable of stimulating T cells in germinal centres. Nature 1996;384(6607):364-7.

57.Groux H, Bigler M, de Vries JE, Roncarolo MG. Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. J Immunol 1998;160(7):3188-93.

58.Haynes BF, Martin ME, Kay HH, Kurtzberg J. Early events in human T cell ontogeny. Phenotypic characterization and immunohistologic localization of T cell precursors in early human fetal tissues. J Exp Med 1988;168(3):1061-80.

59.Hedrick MH, Jennings RW, MacGillivray TE, Rice HE, Flake AW, Adzick NS, Harrison MR. Chronic fetal vascular access. Lancet. 1993 Oct 30;342(8879):1086-7.

60.Hochrein H, Shortman K, Vremec D, Scott B, Hertzog P, O'Keeffe M. Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol 2001;166(9):5448-55.

61.Holder MJ, Knox K, Gordon J. Factors modifying survival pathways of germinal center B cells. Glucocorticoids and transforming growth factor-beta, but not cyclosporin A or anti-CD19, block surface immunoglobulin-mediated rescue from apoptosis. Eur. J. Immunol (1992). 22:2725–28

62.Holler E, Roncarolo MG, Hintermeier-Knabe R, et al. Prognostic significance of increased IL-10 production in patients prior to allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25(3):237-41.

63.Hurley CK, Wade JA, Oudshoorn M, Middleton D, Kukuruga D, Navarrete C, Christiansen F, Hegland J, Ren EC, Andersen I, Cleaver SA, Brautbar C, Raffoux C. Histocompatibility testing guidelines for hematopoietic stem cell transplantation using volunteer donors: report from The World Marrow Donor Association. Quality Assurance and Donor Registries Working Groups of the World Marrow Donor Association. Bone Marrow Transplant. 1999 Jul;24(2):119-21.

64.Illidge TM, Johnson PW. The emerging role of radioimmunotherapy in haematological malignancies. Br J Haematol 2000;108(4):679-88.

65.Inaba K, Turley S, Iyoda T, et al. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000;191(6):927-36.

66.Jankowski RA, Ildstad ST. Current progress in chimerism and donor-specific tolerance. Transplant Proc 1996;28(4):2071-4.

67.Jonuleit H, Schmitt E, Schuler G, Knop J, Enk AH. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000;192(9):1213-22.

68.Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999;20(12):561-7.

69.Kavsak, P., Rasmussen, R. K., Causing, C. G., Bonni, S., Zhu, H., Thomsen, G. H., Kehrl JH, Wakefield LM, Roberts AB, JakowlewS, Alvarez-Mon M, Derynck R,Sporn MB, Fauci AS. 1986. Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth. J. Exp. Med. 163:1037–50

70.Kehrl JH, Roberts AB, Wakefield LM, Jakowlew S, Sporn MB, Fauci AS. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J. Immunol (1986). 137:3855–60

71.Kelsall BL,leon F. Involvement of intestinal dendritic cells in oral tolerance,immunity to pathogenesis, and inflammatory bowel disease.Immunol Rev.2005;206:132-148

72.Krieger NR, Yin DP, Fathman CG. CD4+ but not CD8+ cells are essential for allorejection. J Exp Med 1996;184(5):2013-8.

73.Kondaiah P, Sands MJ, Smith JM, Fields A, Roberts AB, Sporn MB, Melton DA. Identification of a novel transforming growth factor- l (TGF-fl5) mRNA in Xenopus laevis. J Biol Chem. 1990 Jan 15;265(2):1089-93.

74.Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993;75(2):263-74.

75.Kronin V, Winkel K, Suss G, Kelso A, Heath W, Kirberg J, von Boehmer H, Shortman K. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J Immunol 1996;157(9):3819-27.

76.Lanzavecchia A, Sallusto F. The instructive role of dendritic cells on T cell responses: lineages, plasticity and kinetics. Curr Opin Immunol 2001;13(3):291-8.

77.Latchman, Y., C.R. Wood, T. Chernova, D. Chaudhary, M. Borde, I. Chernova, Y. Iwai, A.J. Long, J.A. Brown, R. Nunes, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol. 2001. 2:261–268.

78.Lee PW, Cina RA, Randolph MA, Goodrich J, Rowland H, Arellano R, Kim HB, Sachs DH, Huang CA. Stable multilineage chimerism across full MHC barriers without graft-versus-host disease following in utero bone marrow transplantation in pigs. Exp Hematol. 2005 Mar;33(3):371-9.

79.Lee WC, Zhong C, Qian S, et al. Phenotype, function, and in vivo migration and survival of allogeneic dendritic cell progenitors genetically engineered to express TGF-beta. Transplantation 1998;66(12):1810-7.

80.Letterio John J. and Roberts Anita B. REGULATION OF IMMUNERESPONSES BY TGF-. Annu. Rev. Immunol. 1998. 16:137–61

81.Liang Y, Huang T, Zhang C, Todorov I, Atkinson M, Kandeel F, Forman S, Zeng D. Donor CD8+ T cells facilitate induction of chimerism and tolerance without GVHD in autoimmune NOD mice conditioned with anti-CD3 mAb. Blood 2005;105(5):2180-8.

82.Lin, H. Y., Wang, X-F., Ng-Eaton, E., Weinberg, R. A., Lodish, H. F. Expression cloning of the TGF- type II receptor, a functional transmembrane serine/threonine kinase. Cell 68 (1992), 775–785.

83.Lin TJ, Befus AD. Differential regulation of mast cell function by IL-10 and stem cell factor. J Immunol 1997;159(8):4015-23.

84.Linch DC, Rodeck CH, Nicolaides K, Jones HM, Brent L. Attempted bone-marrow transplantation in a 17-week fetus. Lancet 1986;2(8521-22):1453.

85.Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991;173(3):721-30.

86.Lomo J, Blomhoff HK, Beiske K, Stokke T, Smeland EB. TGF-1 and cyclic AMPpromote apoptosis in resting human B lymphocytes. J. Immunol (1995). 154:1634–43

87.Lovell KL, Kraemer SA, Leipprandt JR, et al. In utero hematopoietic stem cell transplantation: a caprine model for prenatal therapy in inherited metabolic diseases. Fetal Diagn Ther 2001;16(1):13-7

88.Lu P, Zucker K, Fuller L, Tzakis A, Esquenazi V, Miller J. Cloning and expression of canine interleukin-10. J Interferon Cytokine Res 1995;15(12):1103-9.

89.Lu L, Li W, Fu F, Chambers FG, Qian S, Fung JJ, Thomson AW. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 1997;64(12):1808-15.

90.Ludewig B, Oehen S, Barchiesi F, Schwendener RA, Hengartner H, Zinkernagel RM. Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells. J Immunol 1999;163(4):1839-44

91.Luo X, Tarbell KV, Yang H, Pothoven K, Bailey SL, Ding R, Steinman RM, Suthanthiran M. Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. Proc Natl Acad Sci U S A. 2007;104(8):2821-6.

92.Lutz MB, Suri RM, Niimi M, Ogilvie AL, Kukutsch NA, Rossner S, Schuler G, Austyn JM. Immature dendritic cells generated with low doses of GM-CSF in the absence of IL-4 are maturation resistant and prolong allograft survival in vivo. Eur J Immunol 2000;30(7):1813-22.

93.Lutz MB, Schuler G. Immature, semi-mature and fully mature dendritic cells: which signals induce tolerance or immunity?Trends Immunol. 2002 Sep;23(9):445-9.

94.Lutzko C, Omori F, Abrams-Ogg AC, et al. Gene therapy for canine alpha-L-iduronidase deficiency: in utero adoptive transfer of genetically corrected hematopoietic progenitors results in engraftment but not amelioration of disease. Hum Gene Ther 1999;10(9):1521-32.

95.Mackey MF, Gunn JR, Maliszewsky C, Kikutani H, Noelle RJ, Barth RJ, Jr. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J Immunol 1998;161(5):2094-8.

96.Magott-Procelewska M. Costimulatory pathways as a basic mechanisms of activating a tolerance signal in T cells. Ann Transplant 2004;9(3):13-8.

97.Matsuda M, Salazar F, Petersson M, et al. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression. J Exp Med 1994;180(6):2371-6.

98.McCartney-Francis N, Mizel D,Wong H, Wahl L, Wahl S. TGF- regulates production of growth factors and TGF- by human peripheral blood monocytes. Growth Factors (1990) 4:27–35

99.Manning, G., Whyte, D.B., Martinez, R., Hunter, T., and Sudarsanam, bound to DNA: insights on DNA binding in TGF- signaling. Cell 94, S. (2002). The protein kinase complement of the human genome. 585–594. Science 298, 1912–1934.

100.Massague J. THE TRANSFORMING GROWTH FACTOR-β FAMILY. Annu. Rev. Cell Biol. 1990. 6 : 597-641

101.Massague´ , J. TGF- signal transduction. Annu. Rev. Bio- H (1998). 67, 753–791.

102.Massague J. How cells read TGF-beta signals. Nat Rev Mol Cell Biol. 2000; 1(3):169-78.

103.Martin PJ, Hansen JA, Storb R, Thomas ED. Human marrow transplantation: an immunological perspective. Adv Immunol 1987;40:379-438.

104.Matthews DC, Appelbaum FR, Eary JF, et al. Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood 1999;94(4):1237-47.

105.Matthes-Martin S, Peters C, Konigsrainer A, et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood 2000;96(12):3997-9.

106.Migliaccio G, Migliaccio AR, Petti S, et al. Human embryonic hemopoiesis. Kinetics of progenitors and precursors underlying the yolk sac----liver transition. J Clin Invest 1986;78(1):51-60.

107.Min WP, Gorczynski R, Huang XY, et al. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000;164(1):161-7.

108.Mou HB, Lin MF, Cen H, Yu J, Meng XJ. TGF-beta1 treated murine dendritic cells are maturation resistant and down-regulate Toll-like receptor 4 expression. J Zhejiang Univ Sci. 2004 Oct;5(10):1239-44.

109.Muench MO, Barcena A. Stem cell transplantation in the fetus. Cancer Control 2004;11(2):105-18.

110.Muench MO, In Utero transplantation:baby steos toward an effective therapy. Bone Marrow Transplant 2005; 36(6):537-47

111.Ohteki T, Fukao T, Suzue K, Maki C, Ito M, Nakamura M, Koyasu S. Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med 1999;189(12):1981-6.

112.Niiro H, Otsuka T, Kuga S, et al. IL-10 inhibits prostaglandin E2 production by lipopolysaccharide-stimulated monocytes. Int Immunol 1994;6(4):661-4.

113.Ogawa H, Soma T, Hosen N, et al. Combination of tacrolimus, methotrexate, and methylprednisolone prevents acute but not chronic graft-versus-host disease in unrelated bone marrow transplantation. Transplantation 2002;74(2):236-43.

114.O'Rourke RW, Kang SM, Lower JA, Feng S, Ascher NL, Baekkeskov S, Stock PG. A dendritic cell line genetically modified to express CTLA4-IG as a means to prolong islet allograft survival. Transplantation 2000;69(7):1440-

115.Owen RD. Immunogenetic consequences of vascular anastomoses between bovine cattle twins. Science 1945; 102: 400–401.

116.Pallavicini MG, Flake AW, Madden D, et al. Hemopoietic chimerism in rodents transplanted in utero with fetal human hemopoietic cells. Transplant Proc 1992;24(2):542-3.

117.Penna G, Adorini L. 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164(5):2405-11.

118.Picus J, Holley K, Aldrich WR, Griffin JD, Letvin NL. A naturally occurring bone marrow-chimeric primate. II. Environment dictates restriction on cytolytic T lymphocyte-target cell interactions. J Exp Med 1985;162(6):2035-52.

119.Pistoia V. Production of cytokines by human B cells in health and disease. Immunol Today 1997;18(7):343-50.

120.Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol 2001;166(9):5327-30.

121.Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95(1):83-9.

122.Pulendran B, Smith JL, Caspary G, Brasel K, Pettit D, Maraskovsky E, Maliszewski CR. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A 1999;96(3):1036-41.

123.Ranges GE, Figari IS, Espevik T, Palladino MA. Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha. J Exp Med. 1987 Oct 1;166(4):991-8.

124.Rea D, van Kooten C, van Meijgaarden KE, Ottenhoff TH, Melief CJ, Offringa R. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 2000;95(10):3162-7.

125.Reid SD, Penna G, Adorini L. The control of T cell responses by dendritic cell subsets. Curr Opin Immunol 2000;12(1):114-21.

126.Roberts AB, Sporn MB. The transforming growth factors- . In Handbook of Experimental Pharmacology. Peptide Growth Factors and Their Receptors, ed. New York: Springer-Verlag (1990). 419–72.

127.Roberts A, Lamb L, Newton D, Sporn M, De Larco J, Todaro G. Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc.Natl.Acad.Sci(1980);77(6):3494-3498

128.Rock KL, Clark K. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway. J Immunol 1996;156(10):3721-6.

129.Rosenzweig, B. L., Imamura, T., Okadome, T., Cox, G. N., Yamashita, H., ten Dijke, P., Heldin, C-H., Miyazono, K. Cloning and characterization of a human type II receptor for bone morphogenetic proteins. Proc. Natl. Acad. Sci. USA (1995), 92, 7632–7636.

130.Rose DM, Fadok VA, Riches DW, Clay KL, Henson PM. Autocrine/ paracrine involvement of plateletactivating factor and transforming growth factor-beta in the induction of phosphatidylserine recognition by murine macrophages. J. Immunol (1995) 155:5819–25

131.Rossini AA, Greiner DL, Mordes JP. Induction of immunologic tolerance for transplantation. Physiol Rev 1999;79(1):99-141.

132.Rudert WA, Kocova M, Rao AS, Trucco M. Fine quantitation by competitive PCR of circulating donor cells in posttransplant chimeric recipients. Transplantation 1994;58(8):964-5.

133.Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol. 2007 May 22. [Epub ahead of print]

134.Saas P, Tiberghien P. Dendritic cells: to where do they lead? Transplantation 2002;73(1 Suppl):S12-5.

135.Sad S, Mosmann TR. Single IL-2- secreting precursor CD4 T cell can develop into either Th1 or Th2 cytokine secretion phenotype. J. Immunol (1994). 153:3514–22

136.Sanchez MJ, Muench MO, Roncarolo MG, Lanier LL, Phillips JH. Identification of a common T/natural killer cell progenitor in human fetal thymus. J Exp Med 1994;180(2):569-76.

137.Satoshi O, Mizutori Y, Takamura N, Yamasaki H, Kita A, Kuwahara H, Nagayama Y. Adenovirus-mediated gene delivery of interleukin-10, but not transforming growth factor beta,ameliorates the induction of Graves’ hyperthyroidism in BALB/c mice. Clin Exp Immunol.2005;141(3):405-411

138.Sayegh MH, Carpenter CB. Role of indirect allorecognition in allograft rejection. Int Rev Immunol 1996;13(3):221-9.

139.Schlitt HJ. Is microchimerism needed for allograft tolerance? Transplant Proc 1997;29(1-2):82-4.

140.Selenko-Gebauer N, Majdic O, Szekeres A, Höfler G, Guthann E, Korthäuer U, Zlabinger G, Steinberger P, Pickl WF, Stockinger H, Knapp W, Stöckl J. B7-H1 (Programmed Death-1 Ligand) on Dendritic Cells Is Involved in the Induction and Maintenance of T Cell Anergy.The Journal of Immunology, 2003, 170: 3637-3644.

141.Seyedin, S. M., Segarini, P. R., Rosen, D. M., Thompson, A. Y., Bentz, H., Graycar, J. 1987. Cartilage-inducing factor-B is a unique protein structurally and functionally related to transforming growth factor-/?. J. Biol. Chem. 262:1946-49

142.Shortman K, Liu YJ. Mouse and human dendritic cell subtypes. Nat Rev Immunol 2002;2(3):151-61.

143.Simonsen M. The acquired immunity concept in kidney homotransplantation. Annals of the New York Academy of Sciences 1955; 59: 448–452.

144.Skipper , H. E.. Perspectives In Cancer Chemotherapy: Therapeutic Design. Cancer Res 1964;24:1295-302.

145.Slavin S, Naparstek E, Ziegler M, Lewin A. Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases--feasibility studies. Bone Marrow Transplant 1992;9 Suppl 1:189-90.

146.Slavin S. Maternal-fetal relationship, natural chimerism and bilateral transplantation tolerance as the basis for non-myeloablative stem cell transplantation. Int J Hematol. 2002;76(suppl 1):172-175.

147.Shields LE, Bryant EM, Easterling TR, Andrews RG. Fetal liver cell transplantation for the creation of lymphohematopoietic chimerism in fetal baboons. Am J Obstet Gynecol 1995;173(4):1157-60.

148.Soares MP, Brouard S, Smith RN, Bach FH. Heme oxygenase-1, a protective gene that prevents the rejection of transplanted organs. Immunol Rev. 2001 Dec;184:275-85.

149.Sorof JM, Koerper MA, Portale AA, Potter D, DeSantes K, Cowan M. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 1995;59(11):1633-5.

150.Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68(4):480-4.

151.Starzl TE, Demetris AJ, Murase N, Trucco M, Thomson AW, Rao AS. The lost chord: microchimerism and allograft survival. Immunol Today 1996;17(12):577-84; discussion 88.

152.Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.

153.Steinman RM. The control of immunity and tolerance by dendritic cell. Pathol Biol (Paris) 2003;51(2):59-60.

154.Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med 1973;137(5):1142-62

155.Stuehr DJ, Nathan CF. Nitric oxide. A macrophage product responsible for cytostasis and respiratory inhibition in tumor target cells. J Exp Med 1989;169(5):1543-55.

156.Suda T, Daddi N, Tagawa T, Kanaan S, Kozower B, Ritter J, Pattersom A. Recipient intramuscular cotransfection of transforming growth factor beta1 and interleukin 10 ameliorates acute lung graft rejection. Journal of throacic and cardiovascularsurgery 2005;129(4):926-931

157.Swain SL, Huston G, Tonkonogy S, Weinberg ATransforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J. Immunol (1991). 147:2991–3000

158.Svendsen UG, Aggestrup S, Heilmann C, et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. J Heart Lung Transplant 1999;18(4):388-90.

159.Sykes M. Hematopoietic cell transplantation for the induction of allo- and xenotolerance. Clin Transplant 1996;10(4):357-63.

160.Takayama T, Nishioka Y, Lu L, Lotze MT, Tahara H, Thomson AW. Retroviral delivery of viral interleukin-10 into myeloid dendritic cells markedly inhibits their allostimulatory activity and promotes the induction of T-cell hyporesponsiveness. Transplantation 1998;66(12):1567-74.

161.Tavassoli M. Embryonic and fetal hemopoiesis: an overview. Blood Cells 1991;17(2):269-81; discussion 82-6.

162.te Velde AA, de Waal Malefijt R, Huijbens RJ, de Vries JE, Figdor CG. IL-10 stimulates monocyte Fc gamma R surface expression and cytotoxic activity. Distinct regulation of antibody-dependent cellular cytotoxicity by IFN-gamma, IL-4, and IL-10. J Immunol 1992;149(12):4048-52.

163.Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr Opin Immunol 2001;13(1):45-51.

164.Thilaganathan B, Abbas A, Nicolaides KH. Fetal blood natural killer cells in human pregnancy. Fetal Diagn Ther 1993;8(3):149-53.

165.Thomson AW, Takayama T. Dendritic cells and the outcome of organ transplantation: a contemporary view. Transplant Proc 1999;31(7):2738-9.

166.Touraine JL, Raudrant D, Royo C, et al. In-utero transplantation of stem cells in bare lymphocyte syndrome. Lancet 1989;1(8651):1382.

167.Touraine JL. In utero transplantation of fetal liver stem cells into human fetuses. J Hematother 1996;5(2):195-9.

168.Tseng, S.Y., M. Otsuji, K. Gorski, X. Huang, J.E. Slansky, S.I. Pai, A. Shalabi, T. Shin, D.M. Pardoll, and H. Tsuchiya. B7-DC, a new dendritic cell molecule with potent co-stimulatory properties for T cells. J. Exp. Med. 2001. 193:839–846.

169.Umemura A, Monaco AP, Maki T. Donor MHC class II antigen is essential for induction of transplantation tolerance by bone marrow cells. J immunol. 2000 May 1;164(9):4452-7.

170.van Dijk BA, Boomsma DI, de Man AJ. Blood group chimerism in human multiple births is not rare. Am J Med Genet 1996;61(3):264-8.

171.van Twuyver E, Kast WM, Mooijaart RJ, Melief CJ, De Waal LP. Induction of transplantation tolerance by intravenous injection of allogeneic lymphocytes across an H-2 class II mismatch. Different mechanisms operate in tolerization across an H-2 class I vs. H-2 class II disparity. Eur J Immunol 1990;20(2):441-4.

172.Waldmann H. Transplantation tolerance-where do we stand? Nat Med 1999;5(11):1245-8.

173.Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N,Wahl LM, Roberts AB, Sporn MB. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc. Natl. Acad. Sci. USA (1987). 84:5788–92

174.Welch GR, Wong HL, Wahl SM. Selective induction of Fc gamma RIII on human monocytes by transforming growth factor-beta. J. Immunol (1990). 144: 3444–48

175.Wiseman DM, Polverini PJ, Kamp DW, Leibovich SJ. Transforming growth factor-beta (TGF) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem. Biophys. Res. Commun (1988). 157:793–800

176.Wood K, Sachs DH. Chimerism and transplantation tolerance: cause and effect. Immunol Today 1996;17(12):584-7; discussion 8.

177.Wrana, J. L. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF receptor for degradation. Mol. Cell 6 (2000), 1365–1375.

178.Yamaguchi Y, Tsumura H, Miwa M,Inaba K. Contrasting effects of TGF-beta 1 and TNF-alpha on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells. 1997;15(2):144-53.

179.Yong Z, Chang L , Mei YX,Yi L. Role and mechanisms of CD4+CD25+ regulatory T cells in the induction and maintenance of transplantation tolerance. Transpl Immunol. 2007 Feb;17(2):120-9. Epub 2006 Oct 4.

180.Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J Exp Med 1996;183(1):87-97.

181.Zuo Z, Wang C, Carpenter D, Okada Y, Nicolaidou E, Toyoda M, Trento A, Jordan SC. Prolongation of allograft survival with viral IL-10 transfection in a highly histoincompatible model of rat heart allograft rejection. Transplantation 2001;71(5):686-91.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top